You are here

  • Home
  • Archive
  • Volume 11, Issue 4
  • Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium–glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabe…

Article metrics

Article menu
XML
Diabetes and endocrinology
Protocol
Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium–glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes

 

Online download statistics by month:

Online download statistics by month: April 2021 to December 2024

AbstractFullPdf
Apr 2021896880354
May 2021303298100
Jun 2021331339186
Jul 202130129799
Aug 202120621479
Sep 2021258259135
Oct 2021257262102
Nov 202116116275
Dec 202117417876
Jan 202217618358
Feb 202220820988
Mar 2022257255141
Apr 202225325294
May 202218618399
Jun 202217618189
Jul 2022159155125
Aug 202215015189
Sep 202216114581
Oct 2022190196104
Nov 202216515484
Dec 202215013771
Jan 202317315984
Feb 2023285278115
Mar 202320620481
Apr 2023253247162
May 2023325312240
Jun 2023242227194
Jul 2023168165110
Aug 2023252226198
Sep 2023297273189
Oct 2023236220132
Nov 2023244228145
Dec 2023175157116
Jan 2024169152117
Feb 2024179145128
Mar 2024203188181
Apr 2024227200151
May 2024295286140
Jun 2024156150109
Jul 202418817493
Aug 202411210085
Sep 202413613398
Oct 2024143136119
Nov 2024178174138
Dec 2024343120
Total999496555474